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Introduction
The heart is a remarkable organ that adapts to the changing hemo-
dynamic needs of the organism throughout life by modulating its 
output. Acute increases in cardiovascular demand are met by an 
increase in cardiac contractility, whereas chronic increases associat-
ed with development, pregnancy, or sustained exercise are accom-
modated by cardiac growth. Despite this apparent plasticity, car-
diovascular diseases are a prime health burden worldwide and are 
anticipated to increase even further (1). Pathologies such as chronic 
hypertension and aortic stenosis similarly induce cardiac growth, 
but while these responses are initially adaptive, they ultimately com-
promise cardiac output, leading to heart failure and death (2).
Since cardiomyocytes (CMs) in the adult heart are generally 
postmitotic (3, 4), cardiac growth is mediated by CM hypertrophy 
rather than proliferation. The defining characteristics of cardiac 
growth (altered contractility, changed geometry, hypertrophy) 
reflect changes in the phenotype of CMs, making this cell type piv-
otal to the hypertrophic response. However, the multicellular com-
position of the heart represents a potent confounder for analyzing 
hypertrophy, as CMs are outnumbered up to 4-fold by non-CMs 
— a ratio that decreases further during pathological hypertrophy 
through a gain of fibroblasts and immune cells and death of CMs. 
Thus, analyses of heart tissue often only identify the composite 
of changes across its constituent cell types. To overcome this and 
allow the study of CM-specific responses in the intact heart, we 
used a powerful method involving fluorescence-assisted cell sort-
ing to selectively isolate CM nuclei (4, 5).
To bring about the extensive morphological, functional, and 
cellular changes associated with pathological or physiological 
hypertrophy, a wholesale reprogramming of the CM transcriptome 
is required. Notably, pathological, but not physiological, hypertro-
phy is characterized by a reexpression of the fetal gene program, 
with possible deleterious consequences for cardiac function (6). 
For example, reexpression of the fetal myosin heavy chain MYH7 
diminishes cardiac contractility, and muscle pyruvate kinase (PKM) 
accompanies a return to an energetically less favorable glycolyt-
ic metabolism (7, 8). It is, however, unclear how CMs depart from 
their adult state. Importantly, a role for the epigenome in the heart 
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Having validated these hypertrophy models, we next profiled 
H3K9me2 and H3K27me3 occupancy using ChIP, followed by 
high-throughput sequencing (ChIP-seq), and this was done specif-
ically in flow-sorted pericentriolar material 1–positive (PCM1+) CM 
nuclei (n = 4 for each) (Supplemental Figure 1, C and D). Consistent 
with studies in other tissues, these histone modifications marked 
broad, homogeneous segments of the genome (Supplemental 
Figure 1, C and E) known as broad local enrichments (BLOCs) 
and large, organized chromatin K9 modifications (LOCKs) (15, 
16). Of note, H3K9me2 and H3K27me3 levels were substantially 
altered in a subset of these genome segments during hypertrophy 
(Figure 1D). The changes were more pronounced in pathological 
hypertrophy than in physiological hypertrophy, however: 9% and 
0.9%, respectively, of the genome showed more than 20% change 
in H3K9me2, and 3.5% and 0.9% showed more than 20% change 
in H3K27me3 (FDR = 10%; Figure 1D). Remarkably, hypertrophy 
induced by AB was almost exclusively associated with a loss of 
H3K9me2. This pervasive loss was also evident by immunofluo-
rescence of heart sections and by immunoblotting, which revealed 
a decrease of 40% to 60% in H3K9me2 levels in CM nuclei upon 
AB (Figure 1E and Supplemental Figure 1F), whereas H3K9me2 
levels remained unchanged with exercise (Figure 1E and Supple-
mental Figure 1G). Likewise, consistent with the lower number 
of BLOCs exhibiting alterations in H3K27me3, global levels of 
H3K27me3 were unaffected by either form of hypertrophy at this 
time point (Supplemental Figure 1, H and I). Changes at other time 
points and of other histone modifications cannot be excluded.
Pathological hypertrophy reduces H3K9me2 at fetal heart genes. 
We next characterized the regions of the genome affected by loss 
of H3K9me2. A systematic ontology term analysis of genes in 
regions that were decreased in H3K9me2 upon AB revealed an 
enrichment of hypertrophy-associated processes including signal-
ing, responses to hormone stimuli, and heart development (Figure 
2A). Genes depleted in H3K9me2 included the fetal gene program 
canonical markers atrial natriuretic peptide (Nppa), brain natri-
uretic peptide (Nppb), and Myh7 (Figure 1D and Figure 2B, and 
Supplemental Figure 1J). These marks thus appear to repress the 
fetal gene program in the adult CM. To establish that H3K9me2 is 
indeed acquired during CM maturation, we profiled a time series 
of postnatal CM nuclei (P1 to adult) for H3K9me2 using ChIP-seq, 
which revealed a widespread gain in H3K9me2 during CM matura-
tion that was particularly evident for LOCKs that showed a loss of 
H3K9me2 upon AB (Figure 2C), including Nppa, Nppb, and Myh7 
(Supplemental Figure 1, K and L). Immunofluorescence analyses 
again underlined the pervasive nature of this H3K9me2 acquisi-
tion (Figure 2D). In conclusion, we observed a widespread and 
substantial loss of H3K9me2 upon hypertrophy induced by AB but 
not by exercise. Our data suggest that pathological hypertrophic 
cues strip CMs of this epigenetic constraint imposed during devel-
opment, thereby enabling a reactivation of the fetal gene program 
and a pathological remodeling of gene expression.
Loss of H3K9me2 correlates with increased transcription in hyper-
trophic cardiomyocytes. To assess whether the epigenetic changes 
observed underlie transcriptional regulation, we next used RNA-
seq to profile transcriptomes of sorted CM nuclei from hearts sub-
jected to physiological and pathological hypertrophy. In addition to 
providing a CM-specific transcriptome, this nuclear RNA also pro-
is increasingly being recognized; for example, histone 3 lysine 
27 methylation is involved in heart development (9), and signal- 
responsive changes in histone deacetylation control gene expres-
sion in cardiac hypertrophy (10). Hypertrophy-associated changes 
in DNA methylation were also reported, although inactivation of the 
DNA methyltransferases Dnmt3a/3b did not affect the hypertrophic 
response (11). Despite this progress, it remains unknown whether 
or how the adult identity of the CM epigenome is lost during and 
contributes to disease. Two important repressive marks, methyl-
ation of lysines 9 and 27 of histone 3 (H3K9me2 and H3K27me3), 
mediate cellular memory by establishing gene programs during 
development that stabilize the differentiated state (12–14). Given 
that pathological hypertrophy in adult CMs is characterized by reex-
pression of fetal-associated transcripts, we hypothesized that this 
reprogramming arises through changes in these stable marks that 
determine and maintain the differentiated state.
By analyzing purified CM nuclei from hypertrophied hearts, 
we identified loss of H3K9me2 as a distinguishing, conserved 
feature of pathological hypertrophy. Moreover, we show that the 
euchromatic histone methyltransferases EHMT1 and EHMT2 (also 
known as GLP and G9a or KMT1C and KMT1D) maintained these 
marks in adult myocytes but that pathological hypertrophic cues 
reduced EHMT1/2 expression posttranscriptionally by activating 
expression of microRNA 217 (miR-217). We found that a reduction 
in EHMT1/2 expression was necessary and sufficient to induce the 
expression of fetal-associated transcripts and pathological hyper-
trophy. Thus, we propose that the EHMT family of H3K9 dimethyl-
transferases “locks” adult CMs in their healthy adult state, protect-
ing them against pathological hypertrophic remodeling.
Results
Pathological hypertrophy reduces H3K9me2 in cardiomyocytes. During 
development, cells become increasingly locked in their terminally 
differentiated state by stable epigenetic marks such as H3K9me2 and 
H3K27me3. To investigate how these marks are altered in different 
forms of hypertrophy, we compared hearts from well-established 
models of pathological and physiological hypertrophy in rats: patho-
logical hypertrophy was triggered over a 6-week period through an 
ascending aortic banding–induced (AB-induced) pressure overload, 
and physiological hypertrophy was induced through a 6-week exer-
cise regime of increasing intensity. Both treatments resulted in a simi-
lar 1.5-fold increase in the left ventricular (LV)/body weight (BW) ratio 
but yielded different functional and structural phenotypic outcomes. 
Specifically, AB-induced hypertrophy was associated with concentric 
cardiac growth, reexpression of the fetal gene program, expression of 
fibrosis-associated markers (both determined by quantitative real-
time PCR [qRT-PCR]), and a moderate reduction in cardiac function 
(ejection fraction [EF], determined by echocardiography) (Figure 
1, A–C, and Supplemental Figure 1, A and B; supplemental material 
available online with this article; doi:10.1172/JCI88353DS1). In con-
trast, exercise stimulated eccentric hypertrophy, without overt acti-
vation of the fetal gene program or fibrosis markers, and enhanced 
cardiac function (Figure 1, A–C, and Supplemental Figure 1, A and B). 
Pathological remodeling induced by AB was intentionally of a mild 
phenotype to allow the study of the mechanistic factors contributing 
to hypertrophy induction, without possible confounding sequelae 
associated with heart failure.
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highly similar intronic RNA transcript counts (Pearson’s r2 = 0.91), 
although, as expected, nuclear RNA was depleted of mitochondri-
al transcribed RNAs (Supplemental Figure 2, A–C). In addition, 
RNA from PCM1+ nuclei was highly enriched in marker genes and 
vided the benefit of establishing levels of active transcription at the 
point of heart removal. Of note, our sorting protocol did not affect 
the nuclear transcriptome, as a comparison between samples before 
and after sorting revealed expression of the same genes as well as 
Figure 1. H3K9me2 is decreased in CMs upon AB in rats. (A) Graphs show LV/BW ratio, normalized to sham or control (mg/g); EF percentage; and ratio of LV 
lumen diameter to myocardial wall thickness at end-diastole. n = 7, 9, 6, and 8 animals for control, exercise, sham, and AB, respectively. (B) M-mode echocar-
diogram showing, at end-diastole, the LV diameter (LVDd) and thickness of the posterior wall (PWd) and of the interventricular septum (IVSd). Horizontal scale 
bars: 0.1 second; vertical scale bars: 2 mm. (C) qRT-PCR showing expression of Nppa, Nppb, Myh6, and Myh7 in the LV. (D) Volcano plot of differential markings 
by H3K9me2 and H3K27me3 of, respectively, LOCKs and BLOCs in PCM1+ nuclei upon pathological (left) and physiological (right) hypertrophy, as determined by 
ChIP-seq. Red and green dots represent regions enriched and depleted upon hypertrophy (FDR <10%; >20% change). (E) Plots show H3K9me2 signal in PCM1+ 
nuclei, determined by immunofluorescence analysis of the LV from AB, sham-operated, exercise, and control animals (n = 4, 5, 3, and 5, respectively). Represen-
tative confocal immunofluorescence images show staining for wheat germ agglutinin (WGA, red) and PCM1 (white), and H3K9me2 (green) in the LV. Scale bars: 
50 μm. Error bars indicate the SEM. n = 5 (C) and 4 (D) replicates. *P < 0.05, **P < 0.01, and ***P < 0.001, by Student’s t test (A and C) and nested ANOVA (E).
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processes specific to CMs, whereas PCM1– nuclei were enriched in 
markers of other cardiac cell types (fibroblasts and endothelial and 
immune cells), highlighting the purity (>98%) and proper identity 
of our CM nuclei (Supplemental Figure 2, D–G). Overlaying epig-
enomic and transcriptomic profiles revealed that genes and regions 
heavily covered by H3K9me2 or H3K27me3 were transcriptionally 
silent, as anticipated (Figure 3, A and B, Supplemental Figure 2, H 
and I) (17). Notably, however, whereas H3K9me2 levels decreased 
linearly with increasing levels of transcription, H3K27me3 levels 
were consistently low across the expressed genes (Figure 3, A and 
B and Supplemental Figure 2, J and K). This suggests that, in adult 
CMs, H3K9me2 is involved in modulating gene expression levels, 
while H3K27me3 marks an on/off state.
In line with the more marked epigenetic changes observed 
upon AB, we also noted that transcriptomic changes were more 
pronounced in pathological hypertrophy than in physiologi-
cal hypertrophy (Figure 3, C and D), with 705 and 331 protein- 
coding genes (3.1% and 1.4%), respectively, being differentially 
expressed (FDR 10%; Supplemental Tables 1 and 2). A compari-
son between differentially expressed genes here and those found 
in studies in which transcriptional changes were assessed in heart 
tissues confirmed that genes overexpressed in non-CMs were 
overrepresented in tissue-based profiles but not in our pure CM 
profiles, further validating our sorting approach (Supplemental 
Figure 2L). Genes that increased in expression upon AB included 
established pathological hypertrophy marker genes such as Nppa, 
Nppb, and Myh7 (Figure 3C). These genes were also depleted in 
H3K9me2 (Figure 1D and Figure 2B). A global comparison of 
changes in H3K9me2 and gene expression revealed that regions 
that were decreased in H3K9me2 upon AB were highly enriched in 
genes that were upregulated in response to this intervention (Fig-
ure 3E and  Supplemental Figure 2M), suggesting that H3K9me2 
alterations underlie gene expression changes. Notably, the few 
loci that exhibited gains in H3K9me2 levels upon AB (Figure 1D) 
were associated with 61 genes that were either not expressed in 
the heart (including genes involved in olfaction) or expressed at 
very low levels. Ontological analysis of genes upregulated upon 
AB revealed that they encode proteins involved in a diverse array 
of processes including heart contraction, cardiac morphogene-
sis, and signaling, processes that were similarly enriched among 
genes showing an AB-associated loss of H3K9me2 (Figure 3F). 
To further determine whether genes that lose H3K9me2 upon AB 
are part of the wider transcriptional program of the fetal heart, 
we also assessed their expression during in vitro differentiation of 
embryonic stem cells (ESCs) into CMs (18) and during maturation 
of the postnatal heart (19). This assessment revealed that genes 
losing H3K9me2 upon AB were strongly enriched among genes 
that were upregulated during in vitro differentiation into CMs, 
as well as among genes downregulated in the heart after birth 
(P < 10–16 for both; Figure 3, G and H), which was in line with the 
observed gain of H3K9me2 upon CM maturation (Figure 2, C and 
D). Together, these data show that loss of H3K9me2 correlates 
with an overexpression of hypertrophy-induced genes, including 
the fetal gene program. Such transcriptional changes, although 
compensatory at the onset, are considered to reduce the efficien-
cy of CM contraction and metabolism and thus to underlie patho-
logical cardiac remodeling (6).
Figure 2. H3K9me2 is acquired during cardiomyocyte maturation and lost 
at fetal genes upon AB. (A) Selected ontology terms enriched among genes 
in regions altered in H3K9me2 upon AB. (B) H3K9me2 enrichment at loci on 
chromosomes (Chr) 5 and 15 in PCM1+ nuclei. Enrichment is displayed per 
10-kb bin as log2(ratio of AB vs. sham). Green denotes significantly altered 
LOCKs. (C) Changes in H3K9me2 during CM maturation at LOCKs showed 
loss or no loss (green or gray) upon AB. (D) Quantification and representative 
images of immunofluorescence staining of H3K9me2 (green) in CMs (PCM1, 
red) in neonatal (3-day-old) and adult (3-month-old) mice (n = 4 each). 
Hypertrophy was induced for 6 weeks. Error bars indicate the SEM.  
n = 4 (B and D) and 2 (C) replicates. **P < 0.01, by nested ANOVA (D).
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AB, no H3K9me2 demethylases or other methyltransferases were 
altered (24, 25). Together, these findings implicate a loss of EHMT1 
and EHMT2 in the AB-induced loss of H3K9me2, and not a loss of 
other methyltransferases or gain of H3K9me2 demethylases.
EHMTs protect cardiomyocytes from pathological hypertrophy 
in vitro. We next determined whether the observed reduction 
in EHMT1/2 activity following AB is causal for the induction of 
pathological hypertrophy by modulating EHMT1/2 activity and 
abundance. In primary cultures of neonatal rat ventricular myo-
cytes (NRVMs), pathological hypertrophy can be modeled by stim-
ulation of Gq signaling pathways through endothelin 1 (ET-1) appli-
cation (26–28). As observed upon pathological hypertrophy in vivo, 
exposure to ET-1 (100 nM) resulted in the expression of established 
markers of CM hypertrophy. Specifically, ET-1 induced mRNA 
expression of the fetal gene program (Nppa, Nppb, and Myh7, but 
not of the adult isoform Myh6), increased the abundance of atrial 
natriuretic factor (ANF, the product of the Nppa gene), increased 
sarcomere organization, and increased protein synthesis (Figure 
5, A–D). Importantly, as observed during pathological hypertrophy 
in vivo, ET-1 application reduced Ehmt1 and Ehmt2 expression and 
H3K9me2 levels (Supplemental Figure 4, A and B). Next, we inac-
Pathological hypertrophy reduces EHMT1/2 expression. EHMT1 
and EHMT2 are obligate heterodimeric partners that catalyze 
H3K9 dimethylation, predominantly at euchromatic loci at the 
nuclear periphery (20–23). Our ChIP-seq analysis demonstrated 
that upon AB, the majority of H3K9me2 was lost at expressed, 
euchromatic loci. Furthermore, immunofluorescence in AB hearts 
showed that H3K9me2 was predominantly lost at the CM nuclear 
periphery (Supplemental Figure 3A). We therefore assessed the 
expression of Ehmt1/2 in sorted CMs. A profound decrease in RNA 
expression (~60%) of both enzymes was noted upon pathological, 
but not physiological, hypertrophy (Figure 4, A and C). Immu-
nofluorescence and immunoblot analyses confirmed the loss of 
EHMT1/2 proteins upon pathological hypertrophy in CMs (Figure 
4, B and D, and Supplemental Figure 3B). This substantial reduc-
tion in EHMT1/2 expression was sufficient to explain the loss of 
H3K9me2, precluding a requirement to invoke a major contribu-
tion from an altered targeting specificity of EHMT1/2.
We similarly assessed the involvement of H3K9 demethylases 
and other methyl transferases by gene expression analyses (Sup-
plemental Figure 3, C and D). However, while expression of the 
H3K9me3 demethylases Kdm4a and Kdm4b was increased upon 
Figure 3. Hypertrophy-associated transcriptomic changes in flow-sorted rat CMs. (A and B) Violin plots illustrating the gene-wise relation between RNA 
expression and H3K9me2 (A) or H3K27me3 (B). Data were quantified per gene and are represented as log2((fragments + 1) per kb per million) (FPKM). 
(C and D) Gene expression, represented as fragments per million (FPM), in PCM1+ nuclei sorted from hypertrophied and control hearts. Highlighted are 
the genes that were significantly upregulated (green) and downregulated (red) (FDR <10%) after 6 weeks of hypertrophy induction, with characteristic 
genes indicated. (E) Fractions of differentially expressed genes (FDR<10%, difference >20%) in LOCKs with H3K9me2 loss or gain upon AB. (F) Select-
ed ontological terms significantly enriched among genes significantly up- or downregulated in PCM1+ nuclei upon exercise and AB. The gray box before 
each bar represents the P value of enrichment; there are no boxes for P values greater than 0.05. (G and H) Characterization of genes displaying loss of 
H3K9me2 upon AB. (G) Graph represents the fraction of genes that were upregulated during the in vitro differentiation of ESCs into CMs, as determined 
by Wamstad and colleagues (18). (H) Graph shows the fraction of genes that were downregulated in the adult versus newborn heart (19). Data for G and H 
were from the mouse genome. For comparisons with the rat genome, analyses were limited to genes having 1-to-1 paralogs between both species. n = 4. 
*P < 0.05 and ***P < 0.001, by χ2 test.
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tivated EHMTs using a recently developed small molecule, A-366, 
that has potent and specific inhibitory effects on EHMT1 and 
EHMT2 activity in biochemical assays and cultured cells (29, 30). 
A-366 (0.5 μM) decreased H3K9me2 levels in NRVMs, without 
cytotoxicity (Supplemental Figure 4, C and D). Importantly, A-366 
application alone was sufficient to induce hypertrophy: it increased 
protein synthesis, ANF protein expression, sarcomere organi-
zation, as well as Nppa, Nppb, and Myh7, but not Myh6, mRNA 
expression (Figure 5, A–D). This indicates that EHMT1/2 inhibition 
phenocopies the induction of pathological hypertrophy by ET-1. 
Indeed, in contrast, physiological hypertrophy, as induced by 10 
nM insulin-like growth factor 1 application (IGF-1) (31), downreg-
ulated Nppb, upregulated Myh6, and did not affect Myh7, Ehmt1, 
or Ehmt2 expression (Supplemental Figure 4E). The effect of ET-1 
and A-366 upon hypertrophy marker expression was generally not 
summative. Together with the observed reduction of Ehmt expres-
sion upon ET-1 treatment, this indicated that decreased EHMT1/2 
activity is downstream of ET-1. A similar pro-hypertrophic effect 
was observed using a second EHMT1/2 inhibitor, UNC0366 (350 
nM), which is structurally dissimilar to A-366 (Supplemental Fig-
ure 4, F and G) (29, 30). Sufficiency of A-366 or UNC0638 to elicit 
a pathological hypertrophic response in NRVMs strongly suggested 
specificity of the effects observed. Finally, with the aim of rescuing 
the effect of a reduction in EHMTs during pathological hypertro-
phy, we used adenovirus to overexpress EHMT2 in NRVMs (Sup-
plemental Figure 4H). EHMT2 overexpression was sufficient to 
abrogate the ET-1–induced loss of H3K9me2 and the associated 
hypertrophic response (Figure 5, E and F, and Supplemental Figure 
4I), demonstrating that loss of EHMT activity is not only sufficient 
but also necessary to induce a pathological hypertrophic response.
EHMT1/2 inhibition induces pathological cardiac hypertro-
phy. Prompted by our in vitro findings, we next investigated the 
impact of EHMT1/2 inhibition on cardiac hypertrophy in vivo 
in 2 murine models. In a pharmacological model, mice were 
implanted with osmotic minipumps delivering either carrier 
or A-366 (30 mg/kg BW/day), whereas in a genetic model, the 
Ehmt2 locus was specifically and conditionally inactivated in 
CMs of the adult mouse heart (Supplemental Figure 5, A–C). 
Confocal imaging of immunostained tissue sections confirmed 
a reduction in CM H3K9me2 levels by both interventions (Figure 
6, A and B). The reduction in H3K9me2 levels was comparable 
between mice with Ehmt2 loss and those that received A-366, 
indicating a similar efficiency of both methods for EHMT inac-
tivation (Figure 6, A and B). Importantly, EHMT inactivation in 
sham-operated controls induced spontaneous hypertrophy. In 
vivo analysis showed a time-dependent increase in LV wall thick-
ness and a decrease in the lumen/wall thickness ratio and of the 
EF, while a postmortem examination revealed an increase in the 
Figure 4. EHMT1/2 expression is decreased following AB in rats. (A and C) qRT-PCR of Ehmt1 (A) and Ehmt2 (C) mRNA expression in sorted PCM1+ nuclei 
isolated from rats subjected to AB or exercise for 6 weeks. Error bars represent the mean ± SEM of 4 (sham, AB) or 7 (control, exercise) biological replicates. 
*P < 0.05 and **P < 0.01, by Student’s t test. (B and D) (left) Jitter plot illustrating EHMT1 and EHMT2 expression (n = 4 for all conditions) in PCM1+ and 
nesprin+ cardiomyocytes from hearts as in A. P values were calculated using nested ANOVA. Representative images of immunofluorescence staining for 
PCM1 (red) and EHMT1 (green) (B) and nesprin (red) and EHMT2 (green) (D) in LV sections from rats that underwent sham operation or AB. The dashed 
white box indicates the location of the zoomed images (zoom, ×2) to the right of each panel. Scale bars: 50 μm. Nuclei were counterstained with DAPI 
(blue), and CM nuclei are indicated by arrows.
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LV/BW ratio. Together, these parameters indicated a concentric, 
pathological form of hypertrophy that phenocopied AB (Figure 
6, C–E, and Supplemental Figure 5, D–H). The degree of hyper-
trophy paralleled that of established potent hypertrophic agents 
such as isoproterenol and angiotensin II (32) and occurred with-
out blood pressure alterations, indicating a primary hypertro-
phy that was not caused by increased afterload (Supplemental 
Figure 5, I and J). Last, as observed in NRVMs, EHMT inactiva-
tion induced the classical markers for maladaptive hypertrophy 
(including the fetal gene program), as well as fibrosis, and this 
occurred independently of genotype, Cre recombinase activa-
tion, or tamoxifen injection alone (Figure 6, F and G, and Sup-
plemental Figure 5, K and L). Also, a wider set of genes from 
the fetal gene program that were increased upon AB in rat CMs, 
were induced upon CM-specific Ehmt2 KO (Supplemental Fig-
ure 5M). Moreover, genes induced by AB and Ehmt2 KO substan-
tially overlapped with those with increased expression in in vitro 
CM-differentiated ESCs and those downregulated in in vivo 
cardiac maturation. These genes also showed appropriate loss in 
H3K9me2 upon AB (Supplemental Figure 5M).
To assess the impact of EHMT1/2 inactivation on pressure 
overload–induced cardiac remodeling, we performed, in paral-
lel to the sham operations, a banding of the ascending aorta. As 
observed in rats (Figure 4), banding reduced Ehmt1 and Ehmt2 
expression (Supplemental Figure 5N). In addition, H3K9me2 
levels were reduced following banding, although not to the 
same extent as that observed upon exposure to A-366 or inac-
tivation of Ehmt2 alone (Figure 6, A and B). In banded mice, 
A-366 administration or Ehmt2 inactivation did not exacerbate 
the hypertrophic response; there were no or only minor addi-
tional increases in LV weight and no further decrease in the LV 
wall/lumen ratio or in EF (Figure 6D and Supplemental Figure 
5, D–F). In performing these experiments, we noted a slightly 
greater AB-induced hypertrophy in Ehmtfl/fl mice compared with 
mice infused with A-366 or with carrier (Figure 6D). The exper-
iments involving A-366 and Ehmt genetic deletion were not 
Figure 5. Suppression of EHMTs induces 
hypertrophy in vitro. (A and B) Protein 
synthesis (A) and qRT-PCR for Nppa, Nppb, 
Myh6, and Myh7 (B) in primary NRVMs 
exposed for 48 hours to ET-1 or vehicle 
(water) and in response to EHMT1/2 inhibi-
tion (A-366). (C) Immunofluorescence stain-
ing for α-actinin (white) and ANF (green) in 
NRVMs treated with or without ET-1 and/
or A-366. Nuclei were counterstained with 
DAPI (blue). Scale bars: 20 μm. (D) Immuno-
fluorescence signal intensities of perinuclear 
ANF (shown is 1 representative experiment 
from 4 repeats). (E and F) Protein synthesis 
analysis by 3H-leucine incorporation (E) and 
Nppa, Nppb, Myh6, and Myh7 expression 
(F) in NRVMs transduced with empty or 
EHMT2 adenovirus 8 hours prior to agonist 
addition (ET-1 or water). Cells were assayed 
48 hours after agonist addition. Note that 
the hypertrophic response appears damp-
ened in transduced NRVMs compared with 
nontransduced NRVMs in A and B. Error bars 
in A, B, E, and F represent the mean ± SEM. 
n = 5 biological replicates. *P < 0.05, 
**P < 0.01, and ***P < 0.001, by Student’s 
t test.
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pathological hypertrophy was not further augmented by genetic 
or pharmacological inactivation of EHMTs, in keeping with our 
in vitro findings (Figure 6, F and G, and Supplemental Figure 
5L). This suggested that EHMT1/2 loss was integral to the mech-
anism underlying pathological hypertrophy.
miR-217 overexpression destabilizes Ehmt1/2 mRNAs. We next 
investigated how Ehmt1/2 expression was regulated during 
performed at the same time, however, and the effect was due to 
differences in the gradient across the stenosis imposed by the 
banding procedure. Importantly, the gradients were the same 
in animals within each cohort (A-366 experiment and Ehmt-
KO experiment) (Supplemental Figure 5O). Consistent with the 
lack of an additive effect of EHMT loss of function on cardiac 
phenotypic parameters, the expression of molecular markers of 
Figure 6. Pharmacological or genetic inactivation of EHMTs induces pathological hypertrophy. (A and B) H3K9me2 signal in PCM1+ nuclei and representative 
immunofluorescence images for PCM1 (red) and H3K9me2 (green) in sections from LVs of sham- and AB-operated mice (A) after 10 days with A-366 or vehicle 
administration through s.c. mini-osmotic pumps (n = 3 for sham vehicle and 4 for other treatments) and (B) from Ehmt2fl/fl and Ehmt2fl/fl Tg(Myh6-MCM) 
mice [n = 3 for sham-treated Ehmt2fl/fl Tg(Myh6-MCM) mice and n = 4 for all other conditions], 2 weeks after tamoxifen injection. Scale bars: 20 μm. Nuclei are 
stained with DAPI (blue). (C and D) Alterations in LV weight, shape, and EF for sham-operated mice (C) (n = 12, 5, 11, and 11 mice for the indicated conditions) 
and AB-operated mice (D) (n = 10, 5, 10, and 10 mice for the indicated conditions), after 10 days of administration of A-366 or vehicle and for Ehmt2fl/fl and 
Ehmt2fl/fl Tg(Myh6-MCM) mice, 2 weeks after tamoxifen injection. Vertical dashed line indicates experiments conducted separately to inactivate EHMT1/2 by 
chemical or genetic means. To enable comparison within experiments, averaged data for sham-operated animals from C were added to the data in D (grayed 
averages ± SEM). (E) Evolution of LV weight following tamoxifen injection into mice of the indicated genotypes, as estimated by MRI at weeks 0, 1, and 2  
[n = 8 for Ehmt2fl/fl mice and n = 9 for Ehmt2fl/fl Tg(Myh6-MCM) mice]. (F and G) qRT-PCR showing expression levels of Nppa, Nppb, Myh6, Myh7 (F), and colla-
gen, type I, α 1 (Col1a1) (G) in the LVs of Ehmt2fl/fl and Ehmt2fl/fl Tg(Myh6-MCM) mice, 2 weeks after tamoxifen injection and after sham or AB operations. Error 
bars indicate the SEM. n = 5 replicates (F and G). *P < 0.05, **P < 0.01, and ***P < 0.001, by nested ANOVA (A and B) and Student’s t test (C–G).
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hypertrophy. Surprisingly, the observed loss of Ehmt1/2 mRNA 
expression was not evident from our nuclear expression analyses. 
Indeed, qRT-PCR confirmed that nascent Ehmt transcript levels 
were unaltered in CMs upon AB, and likewise in NRVMs upon 
ET-1 treatment (Supplemental Figure 6, A and B). This suggested 
that pathological hypertrophy reduced Ehmt1/2 mRNA expression 
posttranscriptionally, possibly via a miR-dependent mechanism 
(33). To assess whether this effect was through mRNA destabiliza-
tion via the 3′-UTR of Ehmt1/2, we generated luciferase reporter 
constructs harboring the 3′-UTRs of Ehmt1 and Ehmt2 and ana-
lyzed their activity in NRVMs treated with ET-1. Consistent with 
our hypothesis, ET-1 application reduced the luciferase activity 
of both reporters (Figure 7A). To identify the miR responsible for 
this effect, we scanned these 3′-UTRs for miR-binding sites (seed 
sequences) using standard tools (34, 35). Of those identified, 
miR-217 was predicted to target both UTRs (Supplemental Figure 
6C). We functionally confirmed this prediction, as transfection 
of a miR-217 mimic significantly reduced the activity of lucifer-
ase constructs containing either the Ehmt1 or Ehmt2 3′-UTRs in 
HEK293 cells, whereas other predicted miRs were without con-
sistent effects (Figure 7B and Supplemental Figure 6D). Support-
ing its role in hypertrophic remodeling and in line with an earli-
er report suggesting increased expression with AB (36), Mir217 
expression was substantially augmented in vivo upon AB but not 
exercise, and also in vitro in NRVMs upon treatment with ET-1 
but not IGF-1 (Figure 7, C and D). The sufficiency of this increase 
in Mir217 for induction of hypertrophy was next tested. miR-217 
mimic transfection reduced endogenous Ehmt levels in NRVMs 
and concomitantly triggered a pathological hypertrophic response 
(Figure 7E and Supplemental Figure 6E). Importantly, transfec-
tion of NRVMs with a miR-217 antagomir (αmiR-217) significant-
ly blunted the ET-1–induced reduction in luciferase activity of 
both 3′-UTR reporters and of endogenous Ehmt1/2 mRNA levels 
(Figure 7F and Supplemental Figure 6F). Furthermore, miR-217 
antagomir transfection attenuated the concomitant pathological 
hypertrophic response (Figure 7G). These effects of miR-217 were 
mediated by the direct regulation of Ehmt1/2 expression (and 
not through other targets of miR-217), as target site blockers that 
specifically prevent binding of miR-217 to their seed sequence in 
3′-UTRs of Ehmt1/2 also blunted the ET-1–induced hypertrophic 
response (Supplemental Figure 6, G–J).
To examine the relevance of this pathway to hypertrophy in vivo, 
we suppressed miR-217 activity using locked nucleic acid–modified 
antagomirs and assessed the AB-induced hypertrophy. Mice subject-
ed to AB or sham operation were injected with antagomirs targeting 
a scrambled miR or miR-217. This prevented the AB-induced reduc-
tion in EHMT1/2 expression and H3K9me2 levels (Figure 8A and 
Supplemental Figure 7, A and B). While no effects were noted in the 
sham-operated animals, the AB animals receiving miR-217 antag-
omirs showed markedly reduced AB-induced pathological hyper-
trophy and its associated expression of fetal genes when compared 
with their scramble-injected counterparts (Figure 8, B–E), despite 
identical gradients over their banded aorta (3.40 ± 0.03 m/s and 
3.36 ± 0.06 m/s for scrambled and miR-217 antagomirs, respective-
ly) (Supplemental Figure 7C). More specifically, the AB-induced LV 
weight increase was reduced by 46%, the cardiac dimensions (con-
centricity) were better retained, and the decrease in cardiac function 
Figure 7. Downregulation of Ehmt1/2 by miR-217 is required for hyper-
trophy induction in vitro. (A and B) RLU of luciferase constructs harboring 
the 3′-UTR of EHMT1 or EHMT2, transfected into NRVMs treated with 
water or ET-1 (A), or into HEK293 cells transfected with scrambled or 
miR-217 mimic (B). (C and D) Expression of miR-217 in rat CM nuclei sorted 
from sham-operated, AB-operated, control, or exercised hearts (C), and in 
NRVMs treated for 48 hours with ET-1, IGF-1, or water (D). (E) Expression of 
Ehmt1 and Ehmt2 in NRVMs transfected with scrambled or miR-217 mimic 
for 48 hours and treated for 48 hours with ET-1 or water. (F) RLU of lucifer-
ase constructs harboring the 3′-UTR of Ehmt1 or Ehmt2, transfected into 
NRVMs treated with control (anti-scramble; αScr) or miR-217 antagomirs 
(anti–miR-217; αmiR-217). Shown are the RLU in response to 48 hours of 
exposure to ET-1 relative to water-treated controls. (G) Expression of Nppa, 
Nppb, Myh6, and Myh7 in NRVMs treated with control or miR-217 antago-
mirs and exposed for 48 hours to water or ET-1. *P < 0.05, **P < 0.01, and 
***P < 0.001, by Student’s t test. Error bars represent the mean ± SEM of 5 
independent experiments.
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pathological hypertrophic response characterized by cardiac phe-
notypic remodeling and reexpression of the fetal gene program. 
Notably, and consistent with our hypothesis, EHMT1/2 levels 
increased during the maturation of CMs from the fetal to adult 
stage, whereas Mir217 levels decreased, further indicating that this 
gene-regulatory axis is involved in CM maturation (Figure 9A). 
Our data therefore suggest a model in which the activity of EHMTs 
increases during CM maturation to suppress fetal gene expression 
programs and to protect the heart from the pathological hypertro-
phy associated with reexpression of this gene program (Figure 9B).
(EF) was attenuated (Figure 8, B–D). Molecularly, this was mirrored 
by a decreased induction of the fetal heart gene marker panel (Fig-
ure 8E). This demonstrates that countering the Mir217 increase upon 
pathological hypertrophy is sufficient to attenuate the pathological 
hypertrophic response, not only in vitro but also in vivo. These find-
ings indicate that increased expression of Mir217 upon induction of 
pathological hypertrophy reduces expression of Ehmt1/2 mRNAs to 
trigger a pathological hypertrophic response (Figure 8F).
Together, the data delineate a pathway in which miR-217– 
associated loss of EHMT2 expression is sufficient to induce a 
Figure 8. Downregulation of Ehmt1/2 by miR-217 is required for hypertrophy induction in vivo. (A) Effect of miR-217 antagomir or scramble treatment upon 
expression of Ehmt1 and Ehmt2 in hearts from sham- or AB-operated mice 2 weeks after surgery. (B) M-mode echocardiogram from parasternal location of 
mice treated as in A. Indicated are, at end-diastole, the LV diameter (LVDd) and the thickness of the posterior wall (PWd) and of the interventricular septum 
(IVSd). Horizontal scale: 0.1 second; vertical scale: 2 mm. (C) LV mass as estimated by echocardiography (echo) 1 day after AB (before administration of antag-
omirs) and 2 weeks after AB (n = 5 for miR-217– and 8 for scramble-injected animals). (D) LV/BW ratio, LV lumen/wall diameter ratio, and EF of hearts treated 
as in A (n = 4, 4, 8, 5 for the indicated conditions). (E) Expression of Nppa, Nppb, Myh6, and Myh7 in hearts treated as in A. (F) Schematic of miR-217 regulation 
of Ehmt expression and pathological hypertrophy. ***P < 0.001, **P < 0.01, *P < 0.05, and #P = 0.07, by Student’s t test. Error bars in A and E represent the 
mean ± SEM of 4 (sham conditions), 8 (AB plus αScramble), or 6 (AB plus αmiR-217) mice. 
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also induce CM hypertrophy, the phenotype of the pathological 
response is substantially different, as it involves, among others, 
activation of the fetal gene program. What underlies this differ-
ence and how the adult cellular identity is bypassed to give rise to 
hypertrophic remodeling are largely unknown. Here, we identify 
what we believe to be a novel epigenetic-based mechanism that 
determines the different transcriptional responses of CMs during 
the development of physiological and pathological hypertrophy.
With the aim of identifying epigenetic changes that under-
lie phenotypic differences in the hypertrophic response, we pro-
filed repressive histone marks, comparing, for the first time to our 
knowledge, hypertrophy induced by pathological and physiological 
stressors. Hypertrophy was of equivalent magnitude between both 
stimuli, and in the case of pathological hypertrophy was of a mild 
phenotype, since our analysis was aimed at gaining mechanistic 
insights into the development of hypertrophy. We did not study fail-
ing hearts, in which the pathological sequelae may be confounding. 
Performing our analysis on CM nuclei purified from in vivo hyper-
trophied hearts enabled us to directly record changes in the most 
relevant cell type and model. We observed that H3K9me2 was sub-
stantially and pervasively reduced upon pathological, but not phys-
iological, hypertrophy of CMs in vivo. The reduction in H3K9me2 
affected a large fraction of the chromatin (~20% of all genes) and 
was also evident upon immunofluorescence and immunoblot anal-
yses, underlining the magnitude of the loss. Reduced H3K9me2 
affected regions where this mark was acquired during CM matura-
tion, including those encoding fetal gene program markers (Nppa, 
Nppb, and Myh7) that are prototypically upregulated upon patho-
logical hypertrophy. The affected genes were also more broadly 
involved in heart development, contraction, MAPK activity, and 
the response to hormonal stimuli — pathways similarly upregulat-
ed upon pathological hypertrophy. Expression levels of these genes 
were also increased during CM differentiation but downregulated 
in the postnatal heart, further asserting that they are characteris-
tic of the fetal heart. Together, our data reinforce the notion that 
acquisition of H3K9 methylation is key to cells achieving their dif-
ferentiated state. Although changes in epigenetic marks have been 
reported at specific loci and, in a few cases, genome wide (37, 38), 
we demonstrate a direct correlation in CMs between the epigenome 
and the transcriptome that underlies stimulus-specific pathologi-
cal hypertrophy induction. Indeed, the overlaying of nascent RNA 
abundance and its changes during AB with alterations in the epig-
enome allowed us to determine an immediate correlation between 
the epigenome and active transcription at the time point analyzed, 
undiluted by posttranscriptional processes.
The enzymes responsible for depositing H3K9me2, EHMT1 
and EHMT2, were downregulated through an increased expression 
of Mir217 upon pathological, but not physiological, hypertrophy. 
Although previously shown to be upregulated upon hypertrophy 
(36), the role of this miR in heart disease was otherwise unknown. 
miR-217–mediated, pharmacological, and genetic inhibition of 
EHMT1/2, moreover, demonstrated that the observed reduction in 
EHMT1/2 activity was not a mere epiphenomenon, but was suffi-
cient to induce pathological hypertrophy in vitro in NRVMs and in 
vivo in mice. Prevention of the loss of EHMT1/2 during hypertro-
phy through suppression of miR-217 activity also counteracted the 
induction of hypertrophy. Although we do not exclude the possible 
The miR-217/EHMT1/2/H3K9me2 axis is conserved in human car-
diac hypertrophy. To assess the implications of these findings for car-
diac hypertrophy in patients, we studied heart tissues obtained from 
autopsies of deceased males. PCM1+ nuclei were isolated by sorting 
from hypertrophied and normal hearts (Figure 10A and Supplemen-
tal Figure 8A). These purified CM nuclei displayed the anticipated 
changes in expression of fetal gene program markers of hypertrophy 
(Figure 10B). In line with our studies in rodents, nascent EHMT1/2 
transcript levels were unaffected, whereas MIR217 expression 
showed a remarkable 5-fold increase in hypertrophied CMs (Figure 
10, C and D). Elevated MIR217 expression was accompanied by a loss 
of EHMT1/2 mRNA expression and H3K9me2 levels in CMs (Figure 
10, E and F), a pathway that was also sufficient to reduce EHMT1/2 
mRNA and protein expression as well as H3K9me2 levels in a human 
cell line (Supplemental Figure 8, B–D). These data thus indicate 
a functional conservation of the identified miR-217/EHMT1/2/
H3K9me2 axis between rodents and humans.
Discussion
Hypertrophy induced by hypertension or aortic stenosis acts as a 
major risk factor for heart failure. Although physiological stressors 
Figure 9. Gain of Ehmt1/2 expression and loss of miR-217 during CM matu-
ration. (A) qRT-PCR showing expression of Ehmt1, Ehmt2, and Mir217 in CMs 
isolated from rats at the indicated ages, relative to E18. Error bars represent the 
mean ± SEM of 5 biological replicates. ***P < 0.001, **P < 0.01, and *P < 0.05, 
by Student’s t test. (B) Proposed role of EHMT-induced repression of the fetal 
gene program in suppressing pathological hypertrophic remodeling of the heart.
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iological, CM hypertrophy thus highlights that enzymes involved 
in H3K9me2 metabolism represent appealing targets for the treat-
ment of heart disease, either directly or by inhibiting miR-217.
Methods
AB. Male Sprague Dawley rats (~170 g; Taconic) and C57BL/6J mice 
(15–18 g; Janvier and Taconic) were anesthetized, and a 3-0 (rats) or 
8-0 (mice) silk suture was tightened around the ascending aorta prox-
imal to the brachiocephalic trunk. Sham-operated animals served as 
controls. For rats, only those having nonfailing hearts with detect-
able hypertrophy after 6 weeks were retained. For mice, those with a 
mild stenosis (2.5–3.5 m/s in maximal flow velocity over aortic steno-
sis measured on the first or second postoperative day as indicated in 
the Supplemental Methods) and no signs of congestion (left anterior 
descending artery [LAD] <2.0 mm) were included.
Exercise training. Male Sprague Dawley rats (Taconic) Jweighing 
approximately 280 g were assigned to interval training on a treadmill 
(Columbus Instruments) at a 25-degree inclination, with 5 days of 
acclimatization at a running velocity of 6 m/min for 30, 45, 60, 75, 90, 
and 120 minutes. Thereafter, interval training was performed 6 days 
a week in twelve 8-minute intervals, with a 2-minute resting period (6 
m/min) after a warm-up period at 10 m/min. Exercise training was 
performed over a 6-week period at a running speed of 15 m/min that 
was increased by 2 m/min each week.
A-366 treatment, CM-specific Ehmt2 KO, and antagomir delivery. 
On the second postoperative day, mice were stratified by stenosis 
and randomized to a 10-day treatment with either 30 mg/kg/d A-366 
dissolved in 98:2 PEG 400/polysorbate 80 or control treatment with 
98:2 PEG 400/polysorbate 80 without active compound, admin-
istrated s.c. through miniosmotic pumps. Ehmt2fl/fl mice (48) were 
crossed with CM-restricted (Myh6 promoter), tamoxifen-inducible 
MerCreMer-expressing transgenic mice (47) to generate C57BL/6J 
Ehmt2fl/fl Tg(Myh6-MCM) mice. Littermate Ehmt2fl/fl mice were used 
as controls unless otherwise specified. Tamoxifen (40 mg/kg) was 
administrated on the first postoperative day by a single i.p. injec-
tion. To test the in vivo effect of miR-217 upregulation, 7-week-old 
C57BL/6J mice were randomized on the first postoperative day to 
miR-217 or scrambled antagomir treatment, on echocardiographic 
existence of other routes leading to a loss of EHMT1/2 activity, 
our data demonstrate for the first time to our knowledge a potent 
role for miR-217 and the H3K9 dimethyltransferases EHMT1 and 
EHMT2 in the adult heart. EHMTs are essential for normal devel-
opment, and mice with KO of either gene die at E9.5 due to severe 
growth defects (20, 39). In humans, heterozygous loss of EHMT1 
likewise causes multiple developmental anomalies including cardi-
ac defects (40), and we demonstrate here that EHMT1 and EHMT2 
expression levels are downregulated upon pathological hypertro-
phy. Our results contrast with those of a recent study reporting a 
modest increase in Ehmt2 during hypertrophy and alterations of 
H3K9me2 at Myh6 (41). A direct comparison of this study with our 
data is, however, challenging, given the lack of CM-specific analy-
sis, the restriction of analysis solely to the Myh6 locus, as well as the 
differences in animal models analyzed in the other study. EHMT2 
is essential for appropriate differentiation of a wide range of cell 
types including neurons, adipocytes, skeletal myocytes, Th2 cells, 
and photoreceptors (12, 42–45). A recent study similarly implicated 
EHMT1/2 in murine prenatal heart development, although precise 
cellular phenotypes were not described (46). Interestingly, in termi-
nally differentiated neurons, acute loss of EHMTs derepresses the 
expression of a number of neuronal progenitor genes (12), indicating 
that the H3K9me2 mark is necessary not only for the establishment 
but also for the maintenance of a terminally differentiated neuronal 
phenotype. Importantly, EHMT1/2 inhibition in adult neurons as 
well as in brown adipose tissue leads to an ectopic, heterochronic 
expression of fetal CM–specific genes such as Myh7 (12, 13, 47). Our 
current data indicate that EHMTs also repress these fetal CM–spe-
cific genes paratopically in the adult CM.
Altogether, our findings suggest a model wherein H3K9me2 
accumulates during development and keeps the adult CM locked 
in its terminally differentiated state, suppressing the fetal gene 
program. Through pathological hypertrophy–driven expression of 
miR-217 and loss of EHMT1/2, concomitantly with a reduction in 
H3K9me2, the CM genome is derepressed, allowing progression to 
a less differentiated state and providing the basis for a widespread, 
pathological remodeling of the CM transcriptome. The loss of 
H3K9 dimethylation that occurs upon pathological, but not phys-
Figure 10. Loss of EHMT1/2 expression 
and H3K9me2 in human hypertrophic 
hearts. (A) Weight of normal and 
hypertrophic human hearts. (B–E) 
Expression of NPPA, NPPB, MYH6, and 
MYH7 (B), MIR217 (C), and EHMT1 and 
EHMT2 nascent transcripts (D) and 
mature mRNAs (E) in PCM1+ nuclei in 
LVs of normal and hypertrophic human 
hearts. (F) Quantification of H3K9me2 
signal in human CMs. Representative 
images of H3K9me2 staining (green) 
in PCM1+ CM nuclei (red) in normal and 
hypertrophic human hearts. Scale bars: 
20 μm. Error bars represent the mean 
± SEM of 5 (A–E) and 4 (F) biological 
replicates. *P < 0.05, **P < 0.01, and 
***P < 0.001, by Student’s t test (A–E) 
or nested ANOVA (F).
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under The Norwegian Animal Welfare Act, approved by the Norwe-
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5338). Permission for the analysis of human tissue was granted by 
the Regional Ethics Committee in Stockholm, Sweden.
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examination. Locked nucleic acid oligonucleotides (Exiqon) targeting 
miR-217 (AGTTCCTGATGCAGT) or a scrambled control (ACGTC-
TATACGCCCA) were dissolved in PBS (4 mg/ml), and 10 mg/kg was 
injected into the jugular vein 1 and 4 days after surgery. Magnetic res-
onance imaging (MRI) and echocardiography were done 14 days after 
surgery, before hearts were harvested.
Human heart tissues. Heart specimens were provided by the 
Department of Forensic Medicine in Stockholm, Sweden. The myo-
cardial LVs were collected after informed consent from relatives was 
received and were stored at –80°C until further use.
In vitro models of hypertrophy. Ventricular CMs from neonatal (P3) 
Sprague Dawley rats (NRVMs) (obtained from Harlan and Charles River 
Laboratories) were isolated and cultured as described previously (49). 
NRVMs were serum starved for 24 hours and left either unstimulated 
or stimulated for 48 hours with 100 nM ET-1 or 10 nM IGF-1 (both from 
EMD Millipore) in the presence of UNC0638 (350 nM), A-366 (0.5 
μM), or its carrier (DMSO). miR studies were performed as previously 
described (49), using compounds specified in the Supplemental Meth-
ods. EHMT2 was overexpressed through adenoviral transduction, with 
empty virus serving as a control (26). After 8 hours, cells were treated 
with ET-1 and incubated for an additional 48 hours prior to harvesting.
Nuclear isolation and sorting. Nuclei were isolated and sorted from 2 
LV wall samples per experiment: 1 hypertrophic sample and 1 correspond-
ing control sample. Nuclear isolation and sorting were based on a previ-
ously described method (5), as detailed in the Supplemental Methods.
ChIP-seq and RNA-seq. ChIP-seq and strand-specific RNA-seq 
were performed according to standard methods using in-house 
protocols based on NEBnext kits (New England BioLabs Inc.). For-
ty-six bases of these libraries were sequenced on an Illumina HiSeq 
1000 and aligned using Bowtie against the rat genome build 3.4. 
Circular binary segmentation identified LOCKs and BLOCs, and 
differences in histone methylation herein were required to differ by 
at least 20% and to have an FDR-corrected P value below 0.1. Addi-
tional details are provided in the Supplemental Methods. Data are 
available in the NCBI’s Gene Expression Omnibus (GEO) database 
(GEO GSE66653).
Immunofluorescence analyses. Immunofluorescence analyses 
were performed by standard methods, as detailed in the Supple-
mental Methods  and in ref. 49.
Data representation and statistical analysis. Comparisons were made 
using a homoscedastic 2-tailed Student’s t test or ANOVA with a post-
hoc Tukey’s honest significant difference (HSD) test when comparing, 
respectively, 2 or more than 2 conditions. Nested ANOVA was applied to 
immunofluorescence data sets, as multiple measurements per sample 
were available. A P value of less than 0.05 was considered significant.
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Union guidelines and were approved by the Animal Welfare and 
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